Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 5/20 | 0.52 |
| ▸ | TACR3 | P29371 | 1/20 | 0.52 |
| ▸ | MMP9 | P14780 | 2/20 | 0.50 |
| ▸ | MMP8 | P22894 | 2/20 | 0.50 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | APEX1 | P27695 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | THPO | P40225 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22355217 | 1.00 | TACR1 (0.52) | TACR1TACR3MMP9MMP8MMP2 | |
| SCHEMBL24301899 | 0.97 | TACR1 (0.54) | TACR1TACR3MMP9MMP8MMP2 | |
| SCHEMBL24301264 | 0.96 | TACR1 (0.49) | TACR1TACR3MMP9MMP8MMP2 | |
| SCHEMBL24301259 | 0.96 | ERAP2 (0.51) | TACR1TACR3MMP9MMP8MMP2 | |
| SCHEMBL24301896 | 0.95 | MAGI3 (0.52) | TACR1TACR3MMP9MMP8MMP2 | |
| SCHEMBL24301900 | 0.95 | TACR1 (0.49) | TACR1TACR3MMP9MMP8MMP2 | |
| SCHEMBL24301420 | 0.94 | ERAP2 (0.51) | TACR1TACR3MMP9MMP8MMP2 | |
| SCHEMBL24301263 | 0.94 | MMP9 (0.50) | TACR1TACR3MMP9MMP8MMP2 | |
| SCHEMBL24301905 | 0.94 | ACE (0.50) | TACR1TACR3MMP9MMP8MMP2 | |
| SCHEMBL24301392 | 0.94 | TACR1 (0.50) | TACR1TACR3MMP9MMP8MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11760723-B2 | Method of preparing a DON prodrug from L-pyroglutamic acid | DRACEN PHARMACEUTICALS, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20220194898-A1 | METHOD OF PREPARING A DON PRODRUG FROM L-PYROGLUTAMIC ACID | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), AS COLLATERAL AGENT | 2022-06-23 | — | — | US | disclosed |
| US-20220117938-A1 | COMBINATON THERAPY WITH A DON PRODRUG AND AN IMMUNE CHECKPOINT INHIBITOR | DRACEN PHARMACEUTICALS, INC. | 2022-04-21 | — | — | US | disclosed |
| WO-2020167831-A1 | METHOD OF PREPARING A DON PRODRUG FROM L-GLUTAMIC ACID | DRACEN PHARMACEUTICALS, INC. (US) | 2020-08-20 | — | — | WO | disclosed |
| WO-2020167829-A1 | METHOD OF PREPARING A DON PRODRUG FROM L-PYROGLUTAMIC ACID | DRACEN PHARMACEUTICALS, INC. (US) | 2020-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220117938-A1 | COMBINATON THERAPY WITH A DON PRODRUG AND AN IMMUNE CHECKPOINT INHIBITOR | PDCD1, CD274, BID | TACR1 2199/4885TACR3 1029/4885MMP9 3772/4885 |
| US-11760723-B2 | Method of preparing a DON prodrug from L-pyroglutamic acid | GLS, GLS2, GLO1 | TACR1 3288/4885TACR3 4109/4885MMP9 3276/4885 |
| US-20220194898-A1 | METHOD OF PREPARING A DON PRODRUG FROM L-PYROGLUTAMIC ACID | GLS, GLS2, GLO1 | TACR1 3288/4885TACR3 4109/4885MMP9 3276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.